−0.27HKD
−106.08 MHKD
406.86 MHKD
176.01 M
About PURAPHARM CORPORATION LIMITED
Sector
CEO
Yu Ling Chan
Headquarters
Hong Kong
Website
Founded
1998
ISIN
KYG7306Y1044
FIGI
BBG009H9X7M6
PuraPharm Corp. Ltd. is an investment holding company, which engages in the research and development, production and sale of concentrated Chinese medicine granule (CCMG) products and Chinese healthcare products, as well as rendering of Chinese medical diagnostic services. It operates through the following segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics and Plantation. The China CCMG segment manufactures, sells, and researches modernized Chinese medicines in Mainland China. The Hong Kong CCMG segment handles sale of CCMG products excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment consists of operations in Hong Kong, the USA and Japan. The Clinics segment provides Chinese medical diagnostic services. The Plantation segment focuses on the plantation and trading of raw Chinese herbs, and manufacture and sale of TCM decoction pieces. The company was founded by Yu Ling Chan on May 5, 1998 and is headquartered in Hong Kong.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1498 is 0.75 HKD — it has increased by 1.35% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange PURAPHARM CORPORATION LIMITED stocks are traded under the ticker 1498.
PURAPHARM CORPORATION LIMITED is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
1498 stock is 5.33% volatile and has beta coefficient of 0.34. Check out the list of the most volatile stocks — is PURAPHARM CORPORATION LIMITED there?
1498 earnings for the last quarter are 0.03 HKD per share, whereas the estimation was 0.01 HKD resulting in a 228.00% surprise. The estimated earnings for the next quarter are 0.02 HKD per share. See more details about PURAPHARM CORPORATION LIMITED earnings.
PURAPHARM CORPORATION LIMITED revenue for the last quarter amounts to 280.43 M HKD despite the estimated figure of 276.90 M HKD. In the next quarter revenue is expected to reach 319.50 M HKD.
Yes, you can track PURAPHARM CORPORATION LIMITED financials in yearly and quarterly reports right on TradingView.
1498 stock has fallen by 7.41% compared to the previous week, the month change is a 9.64% fall, over the last year PURAPHARM CORPORATION LIMITED has showed a 31.19% decrease.
1498 net income for the last quarter is −68.41 M HKD, while the quarter before that showed −37.68 M HKD of net income which accounts for −81.57% change. Track more PURAPHARM CORPORATION LIMITED financial stats to get the full picture.
Today PURAPHARM CORPORATION LIMITED has the market capitalization of 292.34 M, it has decreased by 1.23% over the last week.
Like other stocks, 1498 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PURAPHARM CORPORATION LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PURAPHARM CORPORATION LIMITED technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PURAPHARM CORPORATION LIMITED stock shows the strong sell signal. See more of PURAPHARM CORPORATION LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PURAPHARM CORPORATION LIMITED EBITDA is −685.00 K HKD, and current EBITDA margin is 0.50%. See more stats in PURAPHARM CORPORATION LIMITED financial statements.